Source: International Congress 2014 – New mechanisms in the pathogenesis of asthma and other lung diseases
Disease area: Airway diseases

Abstract

Background. T lymphocytes are key regulators of the antitumor immunity. Their ability to control local immune response in tumor microenvronment as well as induce tumor cells death is considered the most important .Aim. To evaluate phenotypic properties of AL in NSCLC with particular attention to the markers of T cell cytotoxicity.Methods. Bronchoalveolar lavage fluid (BALF) was harvested in tumor-free lung region from patients with NSCLC (n=15) and healthy volunteers as controls (n=13). AL were phenotyped by flow cytometry for specific surface markers: CD3, CD4, CD8, CD19, CD16, CD56, CD25, CD27 and CD45RO. Cytotoxicity was evaluated in both Th and Tc cells by extracellular (FasL, TRAIL) and intracellular (granzyme B) marker expression.Results. CD4/CD8 ratio was higher in NSCLC patients as compared to controls (1.2±0.3 vs 0.9±0.7 for smokers). AL from NSCLC patients demonstrated increased expression of FasL, (particularly CD4+ cells: 13±7.5 vs 2.3±1.7%, p<0,05), TRAIL (for all AL) and NK cells (8.0±2.1 vs 4.0±1.1%). Granzyme B expression was similar in NSCLC and control groups. Unexpectedly, nTreg (assessed as CD4+25+27+ cells) percentage was lower in NSCLC than in healthy controls.Conclusion. AL from NSCLC patients, including Th cells demonstrate increased cytotoxic potential (FasL+ cells, TRAIL+ cells, NK cells).

Rating:

Share or cite this content

Citations should be made in the following way:
A. Gizycka, J. Chorostowska-Wynimko, C. Rybacki, E. Wedrowska, J. Golinska, P. Kopinski (Warsaw, Bydgoszcz, Poland). Cytotoxic phenotype of alveolar lymphocytes (AL) in bronchoalveolar lavage fluid (BALF) from non-small cell lung cancer (NSCLC) patients. Eur Respir J 2014; 44: Suppl. 58, 3879

Member's Comments

No comment yet.

Related content which might interest you: Evaluation of IL-33 level in serum and bronchoalveolar lavage fluid of patients with non-small cell lung cancer (NSCLC) Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Evaluation of IL-10 level in serum and bronchoalveolar lavage fluid of patients with non-small cell lung cancer (NSCLC) Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Inflammasome pathway activation in patients with non-small cell lung cancer (NSCLC): A bronchoalveolar lavage fluid study Source: Annual Congress 2013 –Pathogenesis and risk of lung cancer Year: 2013 TNF-alpha, IL-1 and IL-6 concentration in bronchoalveolar lavage fluid (BALF) of non-small cell lung cancer (NSCLC) Source: Annual Congress 2013 –New methods for diagnostic workup of lung cancer Year: 2013 Feroptosis of alveolar macrophages in lung cancer Source: International Congress 2016 – Lung cancer and immune cells: friends or foes? Year: 2016 Cytotoxic phenotype of lymphocytes in bronchoalveolar lavage (BAL) of patients with non-small cell lung cancer (NSCLC) Source: International Congress 2017 – Lung cancer - basic science: the latest results from the bench Year: 2017 Decreased apoptosis rate of alveolar lymphocytes (AL) in patients with stage I-IIA non-small cell lung cancer (NSCLC) Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Alvolar lymphocytes (AL) in patients with non-small cell lung cancer (NSCLC). Data from tumor-affected lobe Source: International Congress 2015 – Connective tissue disorders Year: 2015 Increased expression of WSX1 on alveolar lymphocytes (AL) in patients with early stage non-small cell lung cancer (NSCLC). Preliminary report Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Matrix metalloproteinase-9 (MMP-9) elevated in serum, but not in bronchial lavage in lung cancer patients Source: Annual Congress 2013 –New methods for diagnostic workup of lung cancer Year: 2013 Surfactant changes in patients with lung cancer underwent to resection Source: International Congress 2014 – New mechanisms in the pathogenesis of asthma and other lung diseases Year: 2014 Interleukin 27 (IL27) as antitumor tool? Results from bronchoalveolar lavage (BAL) examination Source: International Congress 2016 – Lung cancer and immune cells: friends or foes? Year: 2016 The level of bronchoalveolar lavage fluid prostaglandine E2; Is it diagnostic of bronchogenic carcinoma? Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies Year: 2013 Evaluation of IL-6 level in serum and bronchoalveolar lavage fluid of patients with non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer Year: 2011 Differences in the lipidomic profile of bronchial washing (BW) and bronchoalveolar lavage (BAL) in lung transplanted patients Source: International Congress 2016 – Post-transplant complications: from animal models to the bedside Year: 2016 Utility of bronchoalveolar lavage in the determination of lung asbestos burden in Barcelona, Spain Source: Annual Congress 2013 –Environmental and occupational respiratory diseases: new exposure assessment methods, experimental exposure in animal and humans and mechanisms Year: 2013 CTLA-4 on regulatory T cells - Regulation of local immune response in lung cancer Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer Year: 2015 Transbronchial lung cryobiopsy (TBLC) and bronchoalveolar lavage (BAL) in diagnosis of Intersticial Lung Diseases (ILD) Source: International Congress 2019 – Interventional pulmonology techniques: targeting selective lung tissue Year: 2019 Microparticles as biomarkers of lung injury in human broncho-alveolar lavage fluid Source: International Congress 2014 – Translational studies in COPD Year: 2014 The impact of age on bronchoalveolar lavage (BAL) cytoimmunological pattern in interstitial lung diseases (ILD) and in healthy controls Source: International Congress 2014 – ILDs 4 Year: 2014